[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: Patients with inclusion criteria who received therapeutic regimen of 250 mcg interferon beta 1 b as every other day subcutaneous injection for at least 3 doses and remdesivir 200 mg as first dose then 100 mg daily for 5 days.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: Medication regimen including 250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses plus remdesivir 200 mg as first dose then 100 mg daily for 5 days with Colchicine tablet of Mofid company at dose of 2mg as loading dose then 1 mg daily for 7 days", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 310, "treatment_name": "Colchicine", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]